What is RiconPharma?
Established in 2008 and headquartered in Denville, New Jersey, RiconPharma operates a sophisticated 10,000-square-foot research and development facility. The organization specializes in the development of novel drug delivery systems and the optimization of alternate routes of administration. Beyond initial product development, RiconPharma provides critical support for the life cycle management of approved pharmaceutical products, focusing on modified release dosage forms and product enhancement strategies that address unmet clinical needs.
How much funding has RiconPharma raised?
RiconPharma has raised a total of $2M across 2 funding rounds:
Debt
$1M
Debt
$1M
Debt (2020): $1M with participation from PPP
Debt (2021): $998K led by PPP
Key Investors in RiconPharma
PPP
Public-Private Partnership
What's next for RiconPharma?
With the recent influx of capital, RiconPharma is well-positioned to accelerate its R&D pipeline and expand its technical capabilities. The company is expected to prioritize the scaling of its proprietary drug delivery platforms, ensuring that its portfolio remains at the forefront of pharmaceutical innovation. As the firm navigates the complexities of the current market, this strategic financing will likely facilitate deeper integration into the life cycle management sector, allowing for sustained growth and enhanced competitive positioning in the global healthcare market.
See full RiconPharma company page
